KRAS P.G12D
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. (NCT07456046) | D3 Bio (Wuxi) Co., Ltd | 2026-05-29 |
Track KRAS P.G12D automatically
Every clearance here is in the API, with alerts when new ones post.